MTOR and neoplasm: The direct anti-tumor effects of metformin appear to be modulated through activation of the adenosine monophosphate-activated protein kinase (AMPK) and inhibition of the mammalian target of rapamycin (mTOR) signaling pathway, which leads to inhibition of cell growth and proliferation27.